Mineralys Therapeutics, Inc. Common Stock MLYS

Mineralys Therapeutics, Inc. es una empresa biofarmacéutica en fase clínica. La compañía se enfoca en desarrollar medicamentos para tratar enfermedades causadas por niveles anormalmente elevados de aldosterona. Su candidato a producto, lorundrostat, es un inhibidor de la sintasa de aldosterona (ASI) altamente selectivo, administrado por vía oral y de propiedad exclusiva, que la compañía está desarrollando inicialmente para el tratamiento de pacientes con hipertensión no controlada (uHTN). La compañía completó el ensayo Target-HTN, un ensayo de fase II de prueba de concepto para lorundrostat en el tratamiento de uHTN. Tiene la intención de desarrollar lorundrostat para el tratamiento de la enfermedad renal crónica (CKD).

• GlobeNewswire Inc. 2 oct

  Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026

  Mineralys Therapeutics announced that new data from the Launch-HTN Phase 3 clinical trial of lorundrostat, an investigational aldosterone synthase inhibitor, will be presented at the American Society of Nephrology Kidney Week 2026. The presentation will focus on blood pressure and albuminuria reduction in chronic kidney disease patients. Lorundrostat is being developed to treat uncontrolled and resistant hypertension, with the company having completed six late-stage clinical trials demonstrating efficacy and safety.

  

• GlobeNewswire Inc. 16 sept

  Hypertension Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

  Over 100 pharmaceutical companies are actively developing 110+ pipeline hypertension drugs, with approximately 40+ in late-stage development. Key players include Gossamer Bio, Alnylam Therapeutics, Roche, GSK, and others pursuing novel mechanisms like RNA interference and CRAC channel inhibitors. Recent developments include FDA acceptance of lorundrostat's NDA, initiation of zilebesiran's Phase III cardiovascular outcomes trial, and multiple clinical advances in emerging therapies targeting uncontrolled and resistant hypertension.